AAPA Members, login to view FREE Full Text for all articles. Not a member? Join today!

Institutional members access full text with Ovid®

Share this article on:

Targeted inhibition of the BRAF pathway in a patient with stage IV melanoma

Buckley, Breea, PA-C; Pierce, Bradley, PA-C

Journal of the American Academy of PAs: May 2018 - Volume 31 - Issue 5 - p 24–26
doi: 10.1097/01.JAA.0000530293.13871.69
Case Report

ABSTRACT This article describes the use of vemurafenib, a BRAF inhibitor, to achieve disease regression in a woman with extensive metastatic melanoma and the BRAF V600 gene mutation. Given the improved survival rates seen in these patients, clinicians need to be aware of long-term patient management and adverse reactions to the drug.

At the time this article was written, Breea Buckley was a student in the PA program at Marietta (Ohio) College. Bradley Pierce is an assistant professor in the PA program at Marietta College and practices in the Strecker Cancer Center at Memorial Health System in Marietta, Ohio. The authors have disclosed no potential conflicts of interest, financial or otherwise.

Copyright © 2018 American Academy of Physician Assistants
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website